Jerome Hauer, Emergent BioSolutions Inc. (EBS)’s insider Unloaded 8,375 Shares; Limoneira Co (LMNR) Has 1.32 Sentiment

Emergent BioSolutions Inc. (NYSE:EBS) Logo

Sentiment for Limoneira Co (LMNR)

Limoneira Co (LMNR) investors sentiment increased to 1.32 in Q1 2018. It’s up 0.41, from 0.91 in 2017Q4. The ratio is more positive, as 25 active investment managers increased and opened new holdings, while 19 cut down and sold equity positions in Limoneira Co. The active investment managers in our database now own: 3.46 million shares, up from 3.26 million shares in 2017Q4. Also, the number of active investment managers holding Limoneira Co in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 16 Increased: 16 New Position: 9.

First Wilshire Securities Management Inc holds 0.93% of its portfolio in Limoneira Company for 141,387 shares. Sfe Investment Counsel owns 58,760 shares or 0.72% of their US portfolio. Moreover, New Jersey Better Educational Savings Trust has 0.71% invested in the company for 27,000 shares. The New York-based Teton Advisors Inc. has invested 0.31% in the stock. First Interstate Bank, a Montana-based fund reported 25,000 shares.

Limoneira Company operates as an agribusiness and real estate development firm in the United States and internationally. The company has market cap of $354.17 million. The firm operates through four divisions: Lemon Operations, Other Agribusiness, Rental Operations, and Real Estate Development. It has a 20.92 P/E ratio. The Lemon Operations segment grows, processes, packs, markets, and sells lemons directly to food service, wholesale, and retail customers, as well as packs lemons grown by others.

More news for Limoneira Company (NASDAQ:LMNR) were recently published by: Nasdaq.com, which released: “New Research Coverage Highlights Astec Industries, Prothena Corporation plc, Kornit Digital, Limoneira, Shenandoah …” on June 05, 2018. Businesswire.com‘s article titled: “Limoneira to Announce Second Quarter 2018 Financial Results on June 11, 2018” and published on May 15, 2018 is yet another important article.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $31,410 activity.

Analysts await Limoneira Company (NASDAQ:LMNR) to report earnings on June, 11 after the close. They expect $0.44 earnings per share, up 83.33% or $0.20 from last year’s $0.24 per share. LMNR’s profit will be $6.39 million for 13.85 P/E if the $0.44 EPS becomes a reality. After $-0.09 actual earnings per share reported by Limoneira Company for the previous quarter, Wall Street now forecasts -588.89% EPS growth.

The stock decreased 2.48% or $0.62 during the last trading session, reaching $24.37. About 9,718 shares traded. Limoneira Company (LMNR) has risen 30.26% since June 8, 2017 and is uptrending. It has outperformed by 17.69% the S&P500. Some Historical LMNR News: ; 08/03/2018 – Limoneira Co 1Q Rev $31.6M; 10/04/2018 – LIMONEIRA CO – ANNOUNCED FORMATION OF GRUPO ARGENTINO, A COOPERATIVE ARRANGEMENT BETWEEN CO AND ARGENTINIAN CITRUS GROWERS AND PACKERS; 21/04/2018 – DJ Limoneira Company, Inst Holders, 1Q 2018 (LMNR); 08/03/2018 – LIMONEIRA CO LMNR.O SEES FY 2018 SHR $1.32 TO $1.42; 28/03/2018 – Limoneira Declares Quarterly Dividend; 08/03/2018 – Limoneira Co Raises 2018 View To EPS 65c-EPS 75c; 08/03/2018 – LIMONEIRA CO LMNR.O SEES FY 2018 ADJUSTED SHR $0.65 TO $0.75; 15/03/2018 – Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group Internation; 08/03/2018 Limoneira Co 1Q EPS 58c; 10/04/2018 – Limoneira Announces Formation of Grupo Argentino

Investors sentiment decreased to 1.77 in 2018 Q1. Its down 0.25, from 2.02 in 2017Q4. It is negative, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported. 15,600 were accumulated by Louisiana State Employees Retirement Systems. Pitcairn reported 5,814 shares or 0.03% of all its holdings. Balyasny Asset Management Ltd Limited Liability Company holds 0% in Emergent BioSolutions Inc. (NYSE:EBS) or 6,961 shares. Teacher Retirement Sys Of Texas has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS). Los Angeles Capital & Equity Rech Inc has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). New York-based Virtu Fincl Limited Liability Company has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). Washington State Bank invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Moreover, Aperio Gp Inc Ltd Co has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 14,805 shares. Secor Advisors Limited Partnership owns 36,471 shares. Blackrock Inc invested in 0.01% or 4.47 million shares. Victory Cap Management holds 5,011 shares or 0% of its portfolio. Sei Invests Com holds 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 3,838 shares. Parkside Bank owns 23 shares. Aqr Mngmt Llc invested 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Clarivest Asset Mngmt Ltd reported 0.12% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS).

Among 5 analysts covering Emergent Biosolutions (NYSE:EBS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Emergent Biosolutions has $60 highest and $3300 lowest target. $48.33’s average target is -8.45% below currents $52.79 stock price. Emergent Biosolutions had 10 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Buy” rating by Singular Research on Monday, March 28. Wells Fargo downgraded it to “Hold” rating and $5600 target in Tuesday, April 24 report. The firm earned “Buy” rating on Tuesday, February 27 by Singular Research. Wells Fargo initiated the stock with “Outperform” rating in Friday, February 19 report. Chardan Capital Markets initiated Emergent BioSolutions Inc. (NYSE:EBS) on Friday, April 15 with “Buy” rating. The firm has “Hold” rating by Zacks given on Monday, August 10. Cowen & Co maintained the shares of EBS in report on Friday, July 14 with “Hold” rating. Singular Research maintained the stock with “Buy” rating in Tuesday, June 28 report.

More news for Emergent BioSolutions Inc. (NYSE:EBS) were recently published by: Globenewswire.com, which released: “Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP ..” on May 24, 2018. Streetinsider.com‘s article titled: “Emergent BioSolutions (EBS) in Collanoration with Profectus BioSciences Inc. Secures $25M Contract from CEPI to ..” and published on May 24, 2018 is yet another important article.

Since December 12, 2017, it had 0 insider buys, and 11 selling transactions for $5.18 million activity. Hauer Jerome M also sold $436,876 worth of Emergent BioSolutions Inc. (NYSE:EBS) on Tuesday, June 5. The insider Abdun-Nabi Daniel sold $1.05M. 7,342 Emergent BioSolutions Inc. (NYSE:EBS) shares with value of $389,126 were sold by Richard Ronald. 376 shares were sold by Zoon Kathryn C, worth $19,857 on Wednesday, June 6. Havey Adam also sold $308,574 worth of Emergent BioSolutions Inc. (NYSE:EBS) on Friday, March 9.

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on August, 2. They expect $1.02 earnings per share, up 684.62% or $0.89 from last year’s $0.13 per share. EBS’s profit will be $50.82M for 12.94 P/E if the $1.02 EPS becomes a reality. After $-0.03 actual earnings per share reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts -3,500.00% EPS growth.

The stock decreased 0.85% or $0.45 during the last trading session, reaching $52.79. About 213,830 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 8, 2017 and is uptrending. It has outperformed by 52.96% the S&P500. Some Historical EBS News: ; 19/04/2018 – DJ Emergent BioSolutions Inc, Inst Holders, 1Q 2018 (EBS); 26/03/2018 – Emergent Board of Directors Promotes Robert Kramer Sr. to Newly Created Position of President and Chief Operating Officer; 26/03/2018 – EMERGENT BIOSOLUTIONS – LINDAHL MOST RECENTLY SERVED AS CFO AT CEB INC; 22/03/2018 – EMERGENT BIOSOLUTIONS – TERM OF BOARD AUTHORIZATION OF REPURCHASE PROGRAM IS UNTIL DEC 31, 2019; 21/04/2018 – DJ Emergent Capital Inc, Inst Holders, 1Q 2018 (EMGC); 03/05/2018 – EMERGENT BIOSOLUTIONS INC – REAFFIRMS FULL YEAR 2018 FINANCIAL FORECAST AND OPERATIONAL GOALS; 26/03/2018 – Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy; 21/05/2018 – UROGEN PHARMA LTD – UGN-101 APPEARED TO BE WELL-TOLERATED WITH MOST TREATMENT-EMERGENT ADVERSE EVENTS CHARACTERIZED AS MILD OR MODERATE AND TRANSIENT; 31/05/2018 – SPROTT INVESTS IN EMERGENT TECHNOLOGY HOLDINGS; 24/05/2018 – CEPI – COLLABORATION WITH PROFECTUS BIOSCIENCES INC. AND EMERGENT BIOSOLUTIONS INC

Limoneira Company (NASDAQ:LMNR) Institutional Positions Chart